SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending after reporting strong earnings and authorizing a significant share buyback, which has paradoxically seen its stock decline, igniting community debate over executive stock-based compensation and dilution concerns amidst optimism for its AI/AR Smartglasses innovation and competition from rivals like Meta.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is trending as the community, undeterred by FUD, aggressively champions its role as Solana's privacy layer, citing recent integrations, partnerships for private payments, and an anticipated revenue-sharing model as catalysts for significant future gains.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Recent news of Luckin Coffee's new premium flagship store and a key competitor ending aggressive pricing are fueling optimism for increased margins and market dominance. The community is eagerly discussing a potential uplisting to address the stock's perceived deep undervaluation amidst rapid growth and international expansion.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its recent earnings, which saw an EPS beat but a revenue miss attributed to contract transitions and a government shutdown. This mixed report has led to some investors expressing disappointment, while others view the resulting dip as a buying opportunity, emphasizing the company's substantial $47.2 billion backlog and its pivotal role in key sectors like nuclear energy and space systems for long-term growth.

River is building a chain-abstraction stablecoin system that enables cross-chain collateral, yield, and liquidity—all without bridging.   Powered by the omni-CDP stablecoin satUSD, users can earn, leverage, and scale across different ecosystems natively.   River features the first omni-CDP module that allows users to collateralize assets on Chain A and mint stablecoin satUSD on Chain B—without bridging the assets.

River

RIVER is trending due to recent strategic funding and high-profile backing, alongside ongoing community debate about its innovative stablecoin abstraction system. While many anticipate significant gains fueled by low circulating supply and potential major exchange listings, others foresee a dump, citing concerns over potential token unlocks and supply dynamics.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its Q4 earnings report, where strong profitability and a strategic shift towards prudent risk management were met with a severe market sell-off due to conservative revenue guidance and prevailing fintech sector weakness. The community is sharply divided, with many calling the stock oversold and deeply undervalued while others express frustration over management's outlook and perceived manipulation.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and a lowered fiscal outlook, which has caused a significant stock plunge. The community is sharply divided, with some seeing an extreme overreaction and a buying opportunity, while others warn of severe accounting issues and potential fraud.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is garnering attention following a significant equity financing deal that strengthens its balance sheet and liquidity, building on a record year for retail sales and the expansion of Polestar 4 deliveries. Investors are weighing this positive financial injection and sales growth in several key markets against persistent concerns about the EV maker's path to sustained profitability and intense sector competition.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending as investors anticipate its upcoming earnings report, with widespread debate on whether it will mirror Uber's recent stock performance amid intensifying concerns and opportunities presented by autonomous vehicle advancements. Community discussions are active around its potential as an acquisition target and the impact of its international partnerships.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending following its announced partnership with Palantir for specialized AI data engineering and a prime federal contract with the U.S. Missile Defense Agency. The community is buzzing with anticipation for a potentially explosive Q4 earnings report, expecting significant growth from INOD's critical role in AI data training for government, defense, and sovereign AI initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$207B Market Shift: The Race for Fast Track Approval in Oncology

$207B Market Shift: The Race for Fast Track Approval in Oncology $207B Market Shift: The Race for Fast Track Approval in Oncology PR Newswire VANCOUVER, BC, Feb. 5, 2026 Issued on behalf of...

<ul class="summary-bullets"><li>The company said that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy.&nbsp;</li><li>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally.</li><li>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer.</li></ul><p>Shares of Oncolytics Biotech Inc. (ONCY) rallied 8% at the time of writing ON Wednesday after the company announced that the U.S. Food and Drug Administration has granted a fast track designation to its cancer drug pelareorep in combination with other drugs.</p><p>The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer for whom few effective treatment options exist.</p><h2 class="st-heading-2">Why The Designation?</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/04/3232074/0/en/Oncolytics-Biotech-Receives-FDA-Fast-Track-Designation-for-Pelareorep-in-2L-KRAS-Mutant-MSS-Metastatic-Colorectal-Cancer.html">said</a> that the designation is supported by clinical data which demonstrates a 33% objective response rate for pelareorep-based therapy compared to approximately 10% ORR with standard-of-care in the particular patient population.</p><p>According to Oncolytics, there are an estimated 2 million new colorectal cancer cases each year globally, with an annual total addressable market of approximately $3-5 billion for the subgroup it targets.</p><h2 class="st-heading-2">Plans Ahead</h2><p>The company now intends to initiate a controlled clinical study in the subgroup comparing standard-of-care therapy alone versus standard-of-care plus pelareorep.</p><p>The first clinical site, it noted, is expected to be activated in March, with up to 10 additional sites expected to open shortly thereafter. Interim data from the study are expected by year-end, it added.</p><h2 class="st-heading-2">Perks Of The Designation</h2><p>The Fast Track Designation enables more frequent meetings and communication with the regulator to ensure alignment on development plans and the collection of clinical data needed to support approval. Programs with Fast Track Designation may also be eligible for accelerated approval and priority review if certain criteria are met.</p><p>Pelareorep now has Fast Track Designation for two gastrointestinal cancers including pancreatic cancer. The company is also studying the drug in metastatic breast cancer.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ONCY stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user highlighted high price targets on the stock.</p><p><stembedurl>https://www.stocktwits.com/sk7777777/message/643949165</stembedurl></p><p>According to data from Koyfin, of the seven analysts covering the stock, six have a ‘buy’ or higher rating on the shares of the company while one rates it ‘hold’.</p><p>The stock has an average price target of $5.49, representing a potential upside of over 400% from current trading levels.</p><p><a href="https://stocktwits.com/symbol/ONCY">ONCY stock</a> has gained 32% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ionq-stock-tumbles-as-wolfpack-reveals-short-position/cZbj44zR4NP">IONQ Stock Tumbles 10% As Wolfpack Reveals Short Position</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug

The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for the treatment of certain patients with metastatic colorectal cancer. 

Equity

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks PR Newswire VANCOUVER, BC, Jan. 27, 2026...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Purchases 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger bought 100,000 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was bought at an...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...

Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Acquires 100,000 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger purchased 100,000 shares of the company's stock in a transaction on Friday, January 16th. The stock was acquired at an...

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff PR Newswire VANCOUVER, BC, Jan...

Smart Oncology: 5 Stocks Chasing the $317B Prize

Smart Oncology: 5 Stocks Chasing the $317B Prize Smart Oncology: 5 Stocks Chasing the $317B Prize PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Oncolytics Biotech Inc...

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech, Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.8633
Prev Close	$0.8859
Open	$0.9076
Dividend Yield	0.00%
50-Day Moving Average	$0.9912
Beta	0.90
Avg. Volume	1.3M
PE Ratio	-3.15

52-Week High	$1.51
52-Week Low	$0.3258
Market Capitalization	$95.33M
EPS (Annual)	-$0.3026
Price to Book	1,107.38
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ONCY
Oncolytics Biotech, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ONCY News

ONCYOncolytics Biotech, Inc.